The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors

Published:2023-11 Issue: Volume: Page:
ISSN:2667-0054
Container-title:Journal of the National Cancer Center
language:en
Short-container-title:Journal of the National Cancer Center

Author:

Zhao Ruizhi,Shao Han,Shi Guiqing,Qiu Yanyan,Tang Tianlan,Lin Yuping,Chen Silin,Huang Cheng,Liao Siqin,Chen Jinhua,Fu Haiying,Liu Jianzhi,Xu Benhua,Liu Tingbo,Zhang Yujing^ORCID,Yang Yong^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology,Cancer Research

Reference34 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET;Straus;Blood,2018

3. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma;Engert;N Engl J Med,2010

4. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results;Advani;Blood,2021

5. A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma;Won;Ann Hematol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP